Avidity Biosciences Analyst Ratings
TD Cowen Maintains Avidity Biosciences(RNA.US) With Buy Rating, Raises Target Price to $78
TD Cowen Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $56
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $56 to $75
Analysts' Top Healthcare Picks: DocGo (DCGO), Avidity Biosciences (RNA)
Analysts Conflicted on These Healthcare Names: LivaNova (LIVN), Johnson & Johnson (JNJ) and Avidity Biosciences (RNA)
Goldman Sachs Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $59
Cantor Fitzgerald Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $96
Cantor Fitzgerald Reaffirms Their Buy Rating on Avidity Biosciences (RNA)
Avidity Biosciences Analyst Ratings
Wells Fargo Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $75
Avidity Biosciences Price Target Maintained With a $96.00/Share by Cantor Fitzgerald
Barclays Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $63
Barclays Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $63
Analysts' Top Healthcare Picks: Addex Therapeutics (ADXN), Avidity Biosciences (RNA)
Avidity Biosciences Analyst Ratings
Evercore Maintains Avidity Biosciences(RNA.US) With Buy Rating, Cuts Target Price to $53
Evercore ISI Trims Price Target on Avidity Biosciences to $53 From $54, Keeps Outperform Rating
BofA Securities Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $51
Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED), Avidity Biosciences (RNA) and Veeva Systems (VEEV)